Quick Answer
Lyra Therapeutics, Inc. reported Stockholders Equity of -$10.72 million for fiscal year 2025.
Lyra Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$10.72M | -192.4% |
| 2024 | $11.59M | -87.0% |
| 2023 | $89.42M | +10.7% |
| 2022 | $80.75M | +135.3% |
| 2021 | $34.32M | -53.9% |
| 2020 | $74.49M | +160.4% |
| 2019 | -$123.34M | -15.2% |
| 2018 | -$107.07M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.33M | -121.0% | -366.8% |
| June 30, 2025 | $1.62M | -94.8% | -58.1% |
| March 31, 2025 | $3.87M | -95.0% | -66.6% |
| December 31, 2024 | $11.59M | -87.0% | -43.8% |
| September 30, 2024 | $20.62M | -75.5% | -33.4% |
| June 30, 2024 | $30.98M | -68.6% | -60.0% |
| March 31, 2024 | $77.50M | +17.3% | -13.3% |
| December 31, 2023 | $89.42M | +10.7% | +6.2% |
- Lyra Therapeutics, Inc. showed a decrease of -192.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Lyra Therapeutics, Inc.’s stockholders equity has grown by 90.0% (from -$107.07 million to -$10.72 million).
- The most recent figure is from Lyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: